CHSRII 📈 UBS(Lux)Fund Solutions – - Overview
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Etf • ISIN: LU2250132763 • Switzerland Equity
CHSRII: Stocks, Bonds, Funds, Equities, ETFs, Investments, Securities
‣ Company URL: http://www.credit-suisse.com ‣ Domicile: Luxembourg ‣ Index Name: Morningstar Switzerland TME NR CHF
Additional Sources for CHSRII ETF
CHSRII ETF Overview
| Market Cap in USD | 0m |
| Category | Switzerland Equity |
| TER | 0.30% |
| IPO / Inception | 2021-02-26 |
CHSRII ETF Ratings
| Growth 5y | 17.3% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | 34.5 |
| Analysts | - |
| Fair Price Momentum | 12.25 CHF |
| Fair Price DCF | - |
CHSRII Dividends
No Dividends PaidCHSRII Growth Ratios
| Growth Correlation 3m | -81% |
| Growth Correlation 12m | 74.9% |
| Growth Correlation 5y | -4% |
| CAGR 5y | 2.91% |
| CAGR/Mean DD 5y | 0.27 |
| Sharpe Ratio 12m | 0.20 |
| Alpha | -10.81 |
| Beta | 0.59 |
| Volatility | 12.09% |
| Current Volume | 3k |
| Average Volume 20d | 23.5k |
What is the price of CHSRII stocks?
As of December 22, 2024, the stock is trading at CHF 13.32 with a total of 3,014 shares traded.
Over the past week, the price has changed by -2.61%, over one month by -0.92%, over three months by -5.43% and over the past year by +5.91%.
As of December 22, 2024, the stock is trading at CHF 13.32 with a total of 3,014 shares traded.
Over the past week, the price has changed by -2.61%, over one month by -0.92%, over three months by -5.43% and over the past year by +5.91%.
Is UBS(Lux)Fund Solutions – a good stock to buy?
Neither. Based on ValueRay Analyses, UBS(Lux)Fund Solutions – is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 17.29 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CHSRII as of December 2024 is 12.25. This means that CHSRII is currently overvalued and has a potential downside of -8.03%.
Neither. Based on ValueRay Analyses, UBS(Lux)Fund Solutions – is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 17.29 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CHSRII as of December 2024 is 12.25. This means that CHSRII is currently overvalued and has a potential downside of -8.03%.
Is CHSRII a buy, sell or hold?
UBS(Lux)Fund Solutions – has no consensus analysts rating.
UBS(Lux)Fund Solutions – has no consensus analysts rating.
What are the forecast for CHSRII stock price target?
According to ValueRays Forecast Model, CHSRII UBS(Lux)Fund Solutions – will be worth about 13.5 in December 2025. The stock is currently trading at 13.32. This means that the stock has a potential upside of +0.98%.
According to ValueRays Forecast Model, CHSRII UBS(Lux)Fund Solutions – will be worth about 13.5 in December 2025. The stock is currently trading at 13.32. This means that the stock has a potential upside of +0.98%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 13.5 | 1% |